- Location
eltrombopag
"-
GSK Has Received Approval for Its Platelet-Boosting Drug Revolade in The Treatment
Jun 14, 2013GlaxoSmithKline has received approval from the UK’s National Institute for Health and Clinical Excellence (NICE), for its platelet-boosting drug Revolade in the treatment of adult bleeding disorder, chronic immune (idiopathic) ...
Tags: Blood Disorder Treatment, Medicine
-
GSK Gained FDA Priority Review Status for The Supplemental New Drug Application
Dec 7, 2012GlaxoSmithKline (GSK), Ligand Pharmaceuticals' partner, has gained FDA priority review status for the supplemental new drug application for Promacta to treat thrombocytopenia in adult patients with chronic hepatitis C virus infection. ...
Tags: GlaxoSmithKline, GSK, promacta, thrombocytopenia
-
GSK Promacta Won FDA Approval as Thrombocytopenia Therapy in Chronic Hepatitis C Patients
Nov 20, 2012GlaxoSmithKline's (GSK) Promacta has won FDA approval as thrombocytopenia therapy in chronic hepatitis C patients. Promacta, brand name of eltrombopag in the US, will enable thrombocytopenia patients suffering from chronic hepatitis C ...
Tags: FDA approval, thrombocytopenia therapy, chronic hepatitis C
-
GlaxoSmithKline Submitted Regulatory Applications for Eltrombopag in US, Europe
Jun 4, 2012Ligand Pharmaceuticals partner GlaxoSmithKline has submitted regulatory applications in the US and European Union for the use of eltrombopag (Promacta/Revolade) to increase platelet counts in patients with hepatitis C. A supplemental ...
Related Products
-
Medical Grade 99% API CAS 496775-61-2 Eltrombopag Powder
-
Factory Supply Pharmaceutical Chemical 99% Raw Material Eltrombopag Powder CAS 496775-61-2 Eltrombopag
-
Manufacturers Supply Pharmaceutical Chemical Raw Material Eltrombopag Powder CAS 496775-61-2 Eltrombopag
-
Eltrombopag Olamine 496775-62-3 High Quality and Competitive Price
-
Pharmaceuticals for FDA/Pmda/EMA/Nmpa Eltrombopag Olamine CAS 496775-62-3
-
Eltrombopag Olamine CAS: 496775-62-3
